Published in Gene Therapy Weekly, December 9th, 2004
"Our aim was to evaluate the feasibility and efficacy of tumor necrosis factor-alpha (TNA-alpha) gene therapy in preventing bladder tumor recurrence using an orthotopic model of bladder cancer," said researchers in Singapore.
"We transiently transfected a murine bladder cancer cell line MB49 with pBud-TNF-alpha using a transfection system consisting of the cationic liposome N-(1-(2,3-dioleoyloxyl)propyl)-N,N,N-trimethylammoniummethyl sulfate (DOTAP) plus methyl-beta-cyclodextrin solubilized cholesterol (MBC). MB49 cells produced 893.7±24.0 pg/ml of TNF-alpha 2 days...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.